Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen

S. A. Gregory, J. Vose, M. Modiano, K. Kraemer, R. Rifkin, A. Rubin, T. Menduni, R. Ghalie

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Patients with recurrent lymphoma of any grade were treated with mitoxantrone (12 mg/m2 given intravenously (IV) over 15-30 minutes on day 1) followed by fludarabine at a dose of (25 mg/m 2 given IV over 30 minutes on days 1-3) every 28 days fludarabine at a dose of (25 mg/m2 given IV over 30 minutes on days 1-3) every 28 days. All patients had failed one prior chemotherapy regimen that contained either doxorubicin or mitoxantrone, total dose not exceeding 350 mg/m2 doxorubicin or 80 mg/m2 mitoxantrone. mitoxantrone. Thirty one patients (22 with intermediate- or high-grade and 9 with low-grade NHL) were enrolled. Median age was 63 years (range: 21 to 87). The objective response rate for patients with intermediate/high-grade NHL was 55% (27% with CR) and 89% (56% with CR) for patients with low-grade NHL. Median time to disease progression was 5.1 months for patients with intermediate/high-grade NHL and 10.8 months for patients with low-grade NHL. Median time to death for patients with intermediate/high-grade disease was 11.4 months. Median time to death for patients with low-grade NHL was not calculable as only one death (due to respiratory failure) occurred in this group 6.5 months after study start. The regimen was well tolerated. Grade 3/4 neutropenia was reported in 80% (24 of 30) of patients and Grade 3/4 thrombocytopenia in 19% (6 of 31) of patients. Nine hospitalization for adverse events (primarily fever and neutropenia) occurred among eight patients, all with intermediate/high-grade NHL, during a total of 118 cycles of therapy. Further studies of this combination regimen in patients with intermediate/high-grade NHL and studies combined with monoclonal antibodies in low-grade NHL are warranted.

Original languageEnglish (US)
Pages (from-to)315-324
Number of pages10
JournalLeukemia and Lymphoma
Volume40
Issue number3-4
DOIs
StatePublished - Jan 1 2001

Fingerprint

Mitoxantrone
Non-Hodgkin's Lymphoma
Doxorubicin
Therapeutics
Neutropenia
fludarabine
Respiratory Insufficiency
Disease Progression
Lymphoma

Keywords

  • Fludarabine
  • GM-CSF
  • Mitoxantrone
  • Non-Hodgkin's lymphoma
  • Salvage therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen. / Gregory, S. A.; Vose, J.; Modiano, M.; Kraemer, K.; Rifkin, R.; Rubin, A.; Menduni, T.; Ghalie, R.

In: Leukemia and Lymphoma, Vol. 40, No. 3-4, 01.01.2001, p. 315-324.

Research output: Contribution to journalArticle

Gregory, S. A. ; Vose, J. ; Modiano, M. ; Kraemer, K. ; Rifkin, R. ; Rubin, A. ; Menduni, T. ; Ghalie, R. / Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen. In: Leukemia and Lymphoma. 2001 ; Vol. 40, No. 3-4. pp. 315-324.
@article{8bbbf9b53a454fb489438d9fe6867d13,
title = "Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen",
abstract = "Patients with recurrent lymphoma of any grade were treated with mitoxantrone (12 mg/m2 given intravenously (IV) over 15-30 minutes on day 1) followed by fludarabine at a dose of (25 mg/m 2 given IV over 30 minutes on days 1-3) every 28 days fludarabine at a dose of (25 mg/m2 given IV over 30 minutes on days 1-3) every 28 days. All patients had failed one prior chemotherapy regimen that contained either doxorubicin or mitoxantrone, total dose not exceeding 350 mg/m2 doxorubicin or 80 mg/m2 mitoxantrone. mitoxantrone. Thirty one patients (22 with intermediate- or high-grade and 9 with low-grade NHL) were enrolled. Median age was 63 years (range: 21 to 87). The objective response rate for patients with intermediate/high-grade NHL was 55{\%} (27{\%} with CR) and 89{\%} (56{\%} with CR) for patients with low-grade NHL. Median time to disease progression was 5.1 months for patients with intermediate/high-grade NHL and 10.8 months for patients with low-grade NHL. Median time to death for patients with intermediate/high-grade disease was 11.4 months. Median time to death for patients with low-grade NHL was not calculable as only one death (due to respiratory failure) occurred in this group 6.5 months after study start. The regimen was well tolerated. Grade 3/4 neutropenia was reported in 80{\%} (24 of 30) of patients and Grade 3/4 thrombocytopenia in 19{\%} (6 of 31) of patients. Nine hospitalization for adverse events (primarily fever and neutropenia) occurred among eight patients, all with intermediate/high-grade NHL, during a total of 118 cycles of therapy. Further studies of this combination regimen in patients with intermediate/high-grade NHL and studies combined with monoclonal antibodies in low-grade NHL are warranted.",
keywords = "Fludarabine, GM-CSF, Mitoxantrone, Non-Hodgkin's lymphoma, Salvage therapy",
author = "Gregory, {S. A.} and J. Vose and M. Modiano and K. Kraemer and R. Rifkin and A. Rubin and T. Menduni and R. Ghalie",
year = "2001",
month = "1",
day = "1",
doi = "10.3109/10428190109057930",
language = "English (US)",
volume = "40",
pages = "315--324",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen

AU - Gregory, S. A.

AU - Vose, J.

AU - Modiano, M.

AU - Kraemer, K.

AU - Rifkin, R.

AU - Rubin, A.

AU - Menduni, T.

AU - Ghalie, R.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Patients with recurrent lymphoma of any grade were treated with mitoxantrone (12 mg/m2 given intravenously (IV) over 15-30 minutes on day 1) followed by fludarabine at a dose of (25 mg/m 2 given IV over 30 minutes on days 1-3) every 28 days fludarabine at a dose of (25 mg/m2 given IV over 30 minutes on days 1-3) every 28 days. All patients had failed one prior chemotherapy regimen that contained either doxorubicin or mitoxantrone, total dose not exceeding 350 mg/m2 doxorubicin or 80 mg/m2 mitoxantrone. mitoxantrone. Thirty one patients (22 with intermediate- or high-grade and 9 with low-grade NHL) were enrolled. Median age was 63 years (range: 21 to 87). The objective response rate for patients with intermediate/high-grade NHL was 55% (27% with CR) and 89% (56% with CR) for patients with low-grade NHL. Median time to disease progression was 5.1 months for patients with intermediate/high-grade NHL and 10.8 months for patients with low-grade NHL. Median time to death for patients with intermediate/high-grade disease was 11.4 months. Median time to death for patients with low-grade NHL was not calculable as only one death (due to respiratory failure) occurred in this group 6.5 months after study start. The regimen was well tolerated. Grade 3/4 neutropenia was reported in 80% (24 of 30) of patients and Grade 3/4 thrombocytopenia in 19% (6 of 31) of patients. Nine hospitalization for adverse events (primarily fever and neutropenia) occurred among eight patients, all with intermediate/high-grade NHL, during a total of 118 cycles of therapy. Further studies of this combination regimen in patients with intermediate/high-grade NHL and studies combined with monoclonal antibodies in low-grade NHL are warranted.

AB - Patients with recurrent lymphoma of any grade were treated with mitoxantrone (12 mg/m2 given intravenously (IV) over 15-30 minutes on day 1) followed by fludarabine at a dose of (25 mg/m 2 given IV over 30 minutes on days 1-3) every 28 days fludarabine at a dose of (25 mg/m2 given IV over 30 minutes on days 1-3) every 28 days. All patients had failed one prior chemotherapy regimen that contained either doxorubicin or mitoxantrone, total dose not exceeding 350 mg/m2 doxorubicin or 80 mg/m2 mitoxantrone. mitoxantrone. Thirty one patients (22 with intermediate- or high-grade and 9 with low-grade NHL) were enrolled. Median age was 63 years (range: 21 to 87). The objective response rate for patients with intermediate/high-grade NHL was 55% (27% with CR) and 89% (56% with CR) for patients with low-grade NHL. Median time to disease progression was 5.1 months for patients with intermediate/high-grade NHL and 10.8 months for patients with low-grade NHL. Median time to death for patients with intermediate/high-grade disease was 11.4 months. Median time to death for patients with low-grade NHL was not calculable as only one death (due to respiratory failure) occurred in this group 6.5 months after study start. The regimen was well tolerated. Grade 3/4 neutropenia was reported in 80% (24 of 30) of patients and Grade 3/4 thrombocytopenia in 19% (6 of 31) of patients. Nine hospitalization for adverse events (primarily fever and neutropenia) occurred among eight patients, all with intermediate/high-grade NHL, during a total of 118 cycles of therapy. Further studies of this combination regimen in patients with intermediate/high-grade NHL and studies combined with monoclonal antibodies in low-grade NHL are warranted.

KW - Fludarabine

KW - GM-CSF

KW - Mitoxantrone

KW - Non-Hodgkin's lymphoma

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=0035042387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035042387&partnerID=8YFLogxK

U2 - 10.3109/10428190109057930

DO - 10.3109/10428190109057930

M3 - Article

C2 - 11426553

AN - SCOPUS:0035042387

VL - 40

SP - 315

EP - 324

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -